Rainbow Q1: consolidated revenue +33% YoY to ₹470 Cr; PAT +16% as margins compress on expansion

Rainbow Children's Medicare reported Q1 FY27 (Jun-26) consolidated revenue from operations of ₹469.99 Cr, up 33.2% YoY from ₹352.93 Cr and 2.2% QoQ, comfortably ahead of the ~20% FY27 revenue-growth target management set on the Q4 call. Consolidated PAT rose 16.2% YoY to ₹62.54 Cr (basic EPS ₹5.97 vs ₹5.27). The optically sharp −20% sequential fall in PAT is a tax artefact, not an operating one: Q4 FY26 profit was flattered by a large deferred-tax credit that pushed its effective rate to ~10%, versus a normalised ~25.5% this quarter — pre-tax profit was essentially flat QoQ (₹83.95 Cr vs ₹86.79 Cr).

The gap between 33% revenue and 16% profit growth is the quarter's real story. Operating margin eased to ~28.7% (29.4% a year ago, 31.1% in seasonally strong Q4) and net margin to ~13.0% (14.4% YoY). Much of the topline is inorganic — the consolidation of Prashanthi Medicare (from Jul '25) and Pratiksha Women & Child Care (from Aug '25) plus fresh bed capacity lifts revenue but dilutes margin while new hospitals ramp. Cost of materials (+35.9% YoY), professional fees to doctors (+34.9%) and finance costs (+17.3%) all matched or outpaced revenue. Standalone tells a starker version: standalone PAT was near-flat at ₹52.71 Cr (+1.9% YoY), so effectively all the profit growth sits in subsidiaries — a wide divergence from the consolidated +16% that readers should note.

The stock went into the print at ₹1,520.6, up 7.7% over the past month of trading.

The print lands amid an aggressive expansion cadence announced this week: a 64% stake in Super Prime Medical Care LLP (a running children's hospital in Nellore) for ₹19.8 Cr, a new Malad, Mumbai children's & women's hospital via subsidiary RWCHPL, plus 50 beds added in Guntur and 100 in Mumbai — the LLP and Malad deals expected to close in Q2 FY27. This confirms the capacity-led growth funded from internal accruals that management outlined, but it is also the source of near-term margin dilution as low-occupancy new beds (Q4 occupancy was ~45%) weigh on blended profitability.